New weekly drug tested for knee arthritis pain in adults with extra weight
Tests a once-weekly drug against placebo for knee arthritis in adults with extra weight.
Plain-language title generated from the registry record
Registry title: A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)
Key facts
- Where
- Birmingham, Miami, Shelby, and Tucson, United StatesSee the 4 sites
- Phase
- Phase 3
Where in United States
- Central Alabama ResearchBirmingham, United StatesTaking people
- International Research Associates LLCMiami, United StatesNot yet recruiting
- Carolina Research CenterShelby, United StatesNot yet recruiting
- Noble Clinical Research, LLCTucson, United StatesNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT07915609EU 2026-527180-15-00
- Record updated
- 4 November 2026
- Original description
The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity with and without type 2 diabetes. The study will last 52 weeks and compare the effects of berobenatide compared to placebo on knee pain, physical function, and body weight. Study activities will include blood tests, knee pain assessment, physical function questionnaires and body measurements.Read full original descriptionShow less
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-WEEKLY BEROBENATIDE IN ADULTS WITH KNEE OSTEOARTHRITIS AND OVERWEIGHT OR OBESITY WITH OR WITHOUT TYPE 2 DIABETES (VESPER-OA 2)
The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity with and without type 2 diabetes. The study will last 52 weeks and compare the effects of berobenatide compared to placebo on knee pain, physical function, and body weight. Study activities will include blood tests, knee pain assessment, physical function questionnaires and body measurements.
Inclusion: Adults 18 years of age or older, or the minimum age of consent according to local regulations; Body mass index of at least 27 kg/m² at Screening; Currently meets American College of Rheumatology (ACR) Criteria for knee OA; Pain due to knee OA; Knee radiograph consistent with knee osteoarthritis and Kellgren-Lawrence Grade 2 or 3; Willingness to complete the required analgesic washout; History of at least 1 self-reported unsuccessful dietary effort to lose body weight; HbA1c value at Screening of:; <6.5% (48 mmol/mol) for participants without T2D; ≥6.5% (48 mmol/mol) and <10.0% (86 mmol/mol) for participants with T2D.
Exclusion: Self-reported body weight increase or decrease greater than 5% within 90 days before Screening; Prior target-knee replacement, planned target-knee replacement, or planned elective knee surgery during the study; Prior participation in a berobenatide clinical trial with receipt of active treatment or placebo; Known clinically significant gastric-emptying abnormality, history of acute or chronic pancreatitis, or active symptomatic gallbladder disease; Personal history or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2; Significant active or unstable psychiatric disorder; Condition or knee disorder that could confound assessment of target-knee pain; Hypersensitivity to a drug with glucagon-like peptide-1 receptor activity, including berobenatide, or any excipient; Recent use of weight-loss medication, any glucose-lowering therapy, or other protocol-prohibited treatment; For participants with T2D at Screening only:; Diabetic maculopathy, proliferative diabetic retinopathy, or severe non-proliferative diabetic retinopathy requiring immediate intervention.